Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1997-3-3
|
| pubmed:abstractText |
Small pilot studies of patients with CML have reported on encouraging response rates after treatment with interferon-alpha (IFNalpha) in combination with low-dose cytosine arabinoside (LD ara-C). We therefore initiated a multi-center phase II trial in order to investigate the efficacy and tolerability of this combination in newly diagnosed patients with Ph-positive chronic myelogenous leukemia (CML). Eighty-four patients were treated with IFN-alpha-2c at daily subcutaneous doses of 3.5 MU and LD ara-C added subcutaneously for 10 days every month at a dose of 10 mg/m2, following an initial reduction of WBC to less than 20 x 10(9)/l with hydroxyurea (HU). Within a median observation period of 28 (5-59) months the patients received a median of 7 (1-35) IFNalpha and LD ara-C cycles. Treatment was stopped due to side effects in 16 cases (19%) and to primary or secondary treatment failure in 38 cases (45%). In 45 patients (54%) complete hematological response (CHR) was achieved; in 39 patients (46%) cytogenetic responses including 15 (18%) complete cytogenetic responses (CHR) were observed. Median duration of cytogenetic responses was 15 months. Relapses were seen in 8/15 patients (53%) with complete cytogenetic remission (CCR), in 3/6 patients (50%) with partial cytogenetic response and in 9/18 patients (50%) with minor cytogenetic response. In conclusion, the combination of IFNalpha and LD ara-C resulted in encouraging rates of hematological and cytogenetic responses in patients with CML with low to moderate toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0145-2126
|
| pubmed:author |
pubmed-author:AbbrederisKK,
pubmed-author:ApfelbeckUU,
pubmed-author:BernhartMM,
pubmed-author:DubaCC,
pubmed-author:FluckingerTT,
pubmed-author:FridrikMM,
pubmed-author:GeisslerDD,
pubmed-author:GrünewaldKK,
pubmed-author:GreigWW,
pubmed-author:HausmaningerHH,
pubmed-author:HilbeWW,
pubmed-author:KonwalinkaGG,
pubmed-author:LangAA,
pubmed-author:LinWW,
pubmed-author:LinkeschWW,
pubmed-author:LudwigHH,
pubmed-author:NiederwieserDD,
pubmed-author:NiessnerHH,
pubmed-author:PontJJ,
pubmed-author:SeewannHH,
pubmed-author:SillHH,
pubmed-author:StögerMM,
pubmed-author:ThalerJJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
75-80
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9029189-Adolescent,
pubmed-meshheading:9029189-Adult,
pubmed-meshheading:9029189-Aged,
pubmed-meshheading:9029189-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9029189-Child,
pubmed-meshheading:9029189-Child, Preschool,
pubmed-meshheading:9029189-Cytarabine,
pubmed-meshheading:9029189-Humans,
pubmed-meshheading:9029189-Interferon Type I,
pubmed-meshheading:9029189-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:9029189-Middle Aged,
pubmed-meshheading:9029189-Prospective Studies,
pubmed-meshheading:9029189-Recombinant Proteins,
pubmed-meshheading:9029189-Remission Induction
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
|
| pubmed:affiliation |
Department of Internal Medicine, University Hospital, Innsbruck, Austria.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|